Most Recent
Generic drug maker Sandoz AG has filed proceedings seeking the revocation of two patents registered in Australia by German pharmaceutical giant Bayer covering its top-selling blood clot drug Xarelto.
Bristol-Myers Squib unit Celgene Corporation has sued Indian generics giant Dr Reddy’s Laboratories for allegedly threatening to infringe eight patents for its blockbuster cancer drug Revlimid, which raked in US$12 billion for the US-based company in revenue last year.
Five years into a preliminary discovery application for a potential patent infringement lawsuit over a biosimilar of its Enbrel medication, Pfizer has partially succeeded in obtaining further documents from Samsung Bioepis.
A former executive of hospital operator Healthe Care has been sentenced and fined $10,000 after pleading guilty to one charge of insider trading for acquiring a large number of the company's shares while in possession of inside information regarding plans to acquire a rival hospital operator.
Pharmaceutical ingredient producer Alkaloids of Australia has pleaded guilty to cartel conduct over the supply of a key chemical found in generic stomach cramp drugs.
The Northern Territory government has been hit with a class action alleging it discriminated against Indigenous Australians in Wadeye by failing to provide proper healthcare services.
Johnson & Johnson unit Ethicon will now be on the hook for damages to 11,000 women implanted with defective pelvic mesh devices, after the High Court declined to hear its appeal of a ruling that found it failed to adequately warn about the devices' risks.
Drug company Ono Pharmaceutical has faced tough questioning by an appeals court in a fight with IP Australia over a decision that secured it a patent extension for its cancer immunotherapy drug Opdivo.
A group of 134 workers in healthcare, education and construction have argued a judge should grant them a temporary exemption from Victoria's direction mandating essential employees be vaccinated against COVID-19 to work outside their homes.
A judge has rejected part of IVF provider Virtus Health’s bid for redactions in a recent decision from the court temporarily blocking the company from purchasing rival Adora Fertility, saying some of the confidentiality claims were “staggering” and “border on ridiculous.”